Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dalmau

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 1, 2014
Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testingChristian Pou, Marc Noguera-Julian, Susana Pérez-Álvarez, et al.
Frontiers in Medicine|July 7, 2023
Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort studyRaquel Martín-Iguacel, Mari Carmen Vazquez-Friol, Joaquin Burgos, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2024
Major cardiovascular events after COVID-19 in people with HIVRaquel Martín-Iguacel, Sergio Moreno-Fornés, Andreu Bruguera, et al.
The New England Journal of Medicine|September 12, 2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infectionEsteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 StudyHernando Knobel, José M Miró, Beatriz Mahillo, et al.
Frontiers in Medicine|November 24, 2025
Triglyceride-glucose index and FIB-4 score in relation to cardiovascular disease risk among people with HIV: a retrospective cohort studyMaría Luisa Montes, Carmen Busca, Juan Martín-Torres, et al.
Medical Sciences (Basel, Switzerland)|February 20, 2026
Circulating miRNA Signatures Associated with Atherosclerosis and Cardiometabolic Comorbidities in People with HIVMarina Martinez-Velasco, José Francisco Sánchez-Herrero, Laura Ibañez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 13, 2005
Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 yearsFrancesc Vidal, Joaquim Peraire, Pere Domingo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 25, 2009
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP studyJosep Mallolas, Daniel Podzamczer, Ana Milinkovic, et al.
Clinical and Translational Science|February 5, 2026
Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical TrialLorna Leal, María Del Puerto Bernoy González, Clara Castán, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 1, 2014
Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testingChristian Pou, Marc Noguera-Julian, Susana Pérez-Álvarez, et al.
Frontiers in Medicine|July 7, 2023
Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort studyRaquel Martín-Iguacel, Mari Carmen Vazquez-Friol, Joaquin Burgos, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2024
Major cardiovascular events after COVID-19 in people with HIVRaquel Martín-Iguacel, Sergio Moreno-Fornés, Andreu Bruguera, et al.
The New England Journal of Medicine|September 12, 2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infectionEsteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 StudyHernando Knobel, José M Miró, Beatriz Mahillo, et al.
Frontiers in Medicine|November 24, 2025
Triglyceride-glucose index and FIB-4 score in relation to cardiovascular disease risk among people with HIV: a retrospective cohort studyMaría Luisa Montes, Carmen Busca, Juan Martín-Torres, et al.
Medical Sciences (Basel, Switzerland)|February 20, 2026
Circulating miRNA Signatures Associated with Atherosclerosis and Cardiometabolic Comorbidities in People with HIVMarina Martinez-Velasco, José Francisco Sánchez-Herrero, Laura Ibañez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 13, 2005
Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 yearsFrancesc Vidal, Joaquim Peraire, Pere Domingo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 25, 2009
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP studyJosep Mallolas, Daniel Podzamczer, Ana Milinkovic, et al.
Clinical and Translational Science|February 5, 2026
Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical TrialLorna Leal, María Del Puerto Bernoy González, Clara Castán, et al.
Pageof 8